The incidence of adenocarcinoma of the pancreas in developed countries is rising, and it ranks fourth in mortality among the malignant diseases (Brennan et al, 1989 (Bos, 1990) . Since mutations at codon 12 of the Ki-ras gene occur early in the development of pancreatic adenocarcinoma (Almoguera et al., 1988) and have been described in premalignant mucous cell hyperplasia of the pancreas (Yanagisawa et al., 1993) Oligonucleotide primer sequences (Jordano & Perucho, 1987) K-ras-12-13-3': 5'-TGT TGG ATC ATA TTC GTC CA-3' K-ras-12-13-5': 5'-CCT GCT GAA AAT GAC TGA AT-3' K-ras-1 2-Hybe: 5'-CCT ACG CCA CCA GCT CCA AC-3' K-ras-12-13-3'-internal: 5'-GTC CAC AAA ATG ATT CTG AA-3' K-ras-12-13-3'-WT: 5'-TCA AAG AAT GGT CCT GCA CC-
3'
K-ras-12-1 3-3'-BstNl: 5'-TCA AAG AAT GGT CCT GGA CC-3' K-ras-12-13-5'-BstNl: 5'-ACT GAA TAT AAA CTT GTG GTA GTT GGA CCT-3'
Results
A non-radioactive SSCP assay to detect point mutations at codon 12 of the Ki-ras gene was established using peripheral blood lymphocyte DNA, tumour cell line DNA and paraffinembedded pancreatic adenocarcinoma tissues (Table II) (Table I ). Neither secretions from acute pancreatitis (n = 3) or chronic pancreatitis (n = 5) nor secretions from normal pancreas (n = 6) or cholelithiasis (n = 6) showed aberrant SSCP patterns (Table I and argues against the presence of contaminated products and confirms that the mutations found in pancreatic secretions indeed derived from the tumour.
Based on these findings, a rapid and economical screening strategy was developed. Pancreatic secretions are first examined by PCR and SSCP analysis. This approach is rapid (6 h from centrifugation of secretions) and simple. To confirm these results in an independent reaction (which may be important in the clinical setting) and in cases where no abnormal strands are seen, an enrichment PCR with RFLP analysis is performed, followed by confirmatory direct sequencing to record the type of mutation present. The latter procedure is the only one in which radioactive isotopes are used.
The potential value of this approach is shown by the findings in three patients from our preliminary series. Results obtained from molecular biology examinations were not communicated to clinicians and therefore did not influence clinical decision making. 1. Patient no. 33 was thought to have adenocarcinoma of the pancreas by radiological criteria (Figure 2a ). Neither SSCP nor enriched PCR was able to detect a mutation (Figure 2b The differentiation between radiographic findings caused by chronic inflammation or carcinoma is sometimes very difficult, as these two diseases may share similar clinical and radiological characteristics (Warshaw & del Castillo, 1992) , and the risk of developing carcinoma of the pancreas in patients with chronic pancreatitis is significantly elevated (Lowenfels et al., 1993 
